25 May 2013
Keywords: neurogen, oral, ra, drug, disappoints, usa-based, reported
Article | 21 June 2004
USA-based Neurogen has reported that its oral C5a antagonist, NGD 2000-1, has failed to meet its main objectives in ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
21 June 2004
24 May 2013
© 2013 thepharmaletter.com